3 days Ago By Defense World Staff
Tenon Medical ( NASDAQ:TNON – Free Report ) had its target price reduced by Maxim Group from $22.00 to $8.00 in a report released on Friday morning, Benzinga reports.
They currently have a buy rating on the stock. Separately, Benchmark reaffirmed a “speculative buy” rating and issued a $3.00 price objective on shares of Tenon Medical in a research report on Wednesday, August 14th.
Read Our Latest Stock Report on Tenon Medical Tenon Medical Stock Down 8.1 % Tenon Medical Company Profile ( Get Free Report ) Tenon Medical, Inc, a medical device company, engages in the development of surgical implant systems to treat severe lower back pain in the United States and Puerto Rico. The company offers CATAMARAN SI-Joint Fusion System to fuse sacroiliac joints (SI-Joints) to treat SI-Joint dysfunction that often causes severe lower back pain; and features fixation device that passes through the axial and sagittal planes of the ilium and sacrum, as well as transfixes the SI joints.
Further Reading Five stocks we like better than Tenon Medical 10 Best Airline Stocks to Buy Is Monolithic Power Systems a Screaming Buy After Near 40% Drop? Differences Between Momentum Investing and Long Term Investing Applied Materials Market Capitulates: Now is the Time to Buy How the NYSE and NASDAQ are Different, Why That Matters to Investors 3 Ultra-High Dividend Yield Stocks for the New Year Receive News & Ratings for Tenon Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tenon Medical and related companies with MarketBeat.com's FREE daily email newsletter ..
